IDH2 and neoplasm: A study using a mouse model with combined mutation of TET2, FLT3-ITD, and IDH2-R140Q; thus, triple-transformed leukemia, showed tumor sensitivity both to 5-azacytidine and to IDH2 inhibitor enasidenib.